Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025
Company well-positioned for further progress and broadening of R&D pipeline Cash resources of approximately $455 million as of December 31, 2023 (unaudited) Expected cash runway, including proceeds from recent private placement, into 2H 2027 Top-line data readout from the Phase 3 trial evaluating zanidatamab in HER2-positive gastroesophageal adenocarcinoma (GEA), HERIZON-GEA-01, expected in 2024 Expected regulatory […]